3-((2-(2,3-difluorophenyl)-5H-imidazo[4,5-d]pyridazin-5-yl)methyl)-5-(4-propoxyphenyl)isoxazole | 1105062-76-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-((2-(2,3-difluorophenyl)-5H-imidazo[4,5-d]pyridazin-5-yl)methyl)-5-(4-propoxyphenyl)isoxazole
• 英文别名: 2-(2,3-Difluoro-phenyl)-5-[5-(4-propoxy-phenyl)-isoxazol-3-ylmethyl]-5H-imidazo[4,5-d]pyridazine；3-[[2-(2,3-Difluorophenyl)imidazo[4,5-d]pyridazin-5-yl]methyl]-5-(4-propoxyphenyl)isoxazole；3-[[2-(2,3-difluorophenyl)imidazo[4,5-d]pyridazin-5-yl]methyl]-5-(4-propoxyphenyl)-1,2-oxazole
• CAS: 1105062-76-7
• 化学式: C₂₄H₁₉F₂N₅O₂
• 分子量: 447.444
• InChiKey: JMJUNRIYOKBQDN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  78.9
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  2-(2,3-difluorophenyl)-5H-imidazo[4,5-d]pyridazine 、 3-((2-(2,3-difluorophenyl)-5H-imidazo[4,5-d]pyridazin-5-yl)methyl)-5-(4-propoxyphenyl)isoxazole 在 potassium carbonate 、 盐酸 作用下， 以 N,N-二甲基甲酰胺 、 水 为溶剂， 反应 1.0h， 生成 3-((2-(2,3-difluorophenyl)-5H-imidazo[4,5-d]pyridazin-5-yl)methyl)-5-(4-propoxyphenyl)isoxazole hydrochloride
  参考文献：
  名称：

  Imidazopyridazine Hepatitis C Virus Polymerase Inhibitors. Structure–Activity Relationship Studies and the Discovery of a Novel, Traceless Prodrug Mechanism

  摘要：

  By reducing the basicity of the core heterocycle in a series of HCV NS5B inhibitors, the hERG liability was reduced. The SAR was then systematically explored in order to increase solubility and enable dose escalation while retaining potency. During this exploration, a facile decarboxylation was noted and was exploited as a novel prodnig mechanism. The synthesis and characterization of these prodrugs and their utilization in chronic toxicity studies are presented.

  DOI：

  10.1021/jm401337x
• 作为产物：
  描述：

  methanesulfonic acid 5-(4-propoxy-phenyl)-isoxazol-3-ylmethyl ester 、 2-(2,3-difluorophenyl)-5H-imidazo[4,5-d]pyridazine 生成 3-((2-(2,3-difluorophenyl)-5H-imidazo[4,5-d]pyridazin-5-yl)methyl)-5-(4-propoxyphenyl)isoxazole
  参考文献：
  名称：

  Anti-viral compounds, compositions, and methods of use

  摘要：

  本发明涉及公式（I）的化合物，其药学上可接受的盐和溶剂，其组合物，以及其制备方法和用于治疗至少部分由Flaviviridae病毒家族中的病毒介导的病毒感染的用途。

  公开号：

  US20090074717A1

文献信息

• Processes For The Preparation Of Anti-Viral Compounds And Compositions Containing Them
  申请人：Leivers Martin Robert

  公开号：US20100029655A1

  公开（公告）日：2010-02-04

  Disclosed are processes for the preparation of compounds of formula I and compositions that comprise said compounds of formula I. Also disclosed are processes for the preparation of compounds of formula III and compositions that comprise said compounds of formula III.

  公开了制备公式I化合物的过程以及包含所述公式I化合物的组合物。 还公开了制备公式III化合物的过程以及包含所述公式III化合物的组合物。
• [EN] ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE<br/>[FR] COMPOSÉS ANTIVIRAUX, COMPOSITIONS ET LEURS PROCÉDÉS D'UTILISATION
  申请人：GENELABS TECH INC

  公开号：WO2009011787A1

  公开（公告）日：2009-01-22

  Disclosed are compounds of Formula (I), pharmaceutically acceptable salts and solvates thereof, compositions thereof, and methods for their preparation and uses for treating viral infections mediated at least in part by a virus in the Flaviviridae family of viruses. (I)

  揭示了式（I）的化合物，其药用盐和溶剂化合物，以及其组合物，以及其制备方法和用于治疗至少部分由黄病毒科病毒介导的病毒感染的用途。
• [EN] PROCESSES FOR THE PREPARATION OF ANTI-VIRAL COMPOUNDS AND COMPOSITIONS CONTAINING THEM<br/>[FR] PROCÉDÉS DE PRÉPARATION DE COMPOSÉS ANTIVIRAUX ET COMPOSITIONS LES CONTENANT
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2010006096A1

  公开（公告）日：2010-01-14

  Disclosed are processes for the preparation of compounds of formula I and compositions that comprise said compounds of formula I. See Formula I. Also disclosed are processes for the preparation of compounds of formula III and compositions that comprise said compounds of formula III. See Formula III.

  公开了制备式I化合物的过程和包含该式I化合物的组合物。请参见式I。还公开了制备式III化合物的过程和包含该式III化合物的组合物。请参见式III。
• Anti-viral compounds, compositions, and methods of use
  申请人：Leivers Martin Robert

  公开号：US20090074717A1

  公开（公告）日：2009-03-19

  Disclosed are compounds of Formula (I), pharmaceutically acceptable salts and solvates thereof, compositions thereof, and methods for their preparation and uses for treating viral infections mediated at least in part by a virus in the Flaviviridae family of viruses.

  本发明涉及公式（I）的化合物，其药学上可接受的盐和溶剂，其组合物，以及其制备方法和用于治疗至少部分由Flaviviridae病毒家族中的病毒介导的病毒感染的用途。
• ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE
  申请人：Leivers Martin Robert

  公开号：US20090197880A1

  公开（公告）日：2009-08-06

  Disclosed are compounds of Formula (I), pharmaceutically acceptable salts and solvates thereof, compositions thereof, and methods for their preparation and uses for treating viral infections mediated at least in part by a virus in the Flaviviridae family of viruses.

  本发明涉及公式（I）的化合物，其药学上可接受的盐和溶剂化合物，以及其组合物的制备方法和用于治疗由黄病毒科病毒介导的至少部分病毒感染的用途。